loading page

Continuous Kidney Replacement Therapy in Children with Sinusoidal Obstruction Syndrome After Hematopoietic Cell Transplant: Outcome and Liberation
  • +2
  • Madeleine Heyn,
  • Emily Ashcraft,
  • Cheng Cheng,
  • Rebecca Epperly,
  • LAMA ELBAHLAWAN
Madeleine Heyn
Loyola University Chicago Stritch School of Medicine
Author Profile
Emily Ashcraft
St Jude Children's Research Hospital
Author Profile
Cheng Cheng
St Jude Children's Research Hospital
Author Profile
Rebecca Epperly
St Jude Children's Research Hospital Department of Oncology
Author Profile
LAMA ELBAHLAWAN
St Jude Children's Research Hospital

Corresponding Author:lama.elbahlawan@stjude.org

Author Profile

Abstract

Background: Sinusoidal obstruction syndrome (SOS), a serious complication after hematopoietic cell transplant (HCT), is associated with multi-organ dysfunction (MOD) and a high mortality rate. In severe cases, continuous kidney replacement therapy (CKRT) is initiated to manage fluid overload (FO) and acute kidney injury. Studies that evaluate the use of CKRT in this population are lacking. The aim of our study was to assess the outcome of critically ill children with severe SOS post HCT who received CKRT. We also sought to assess factors associated with survival and liberation post CKRT. Procedure: Retrospective review of all children admitted to the intensive care unit (ICU) with SOS post HCT who received CKRT from January 2010 to August 2022. Results: Among the 53 children who received CKRT post HCT, 13 had severe SOS. The median age was 6 years; 62% were males, and most (77%) received allogeneic HCT. In this cohort, 92% required respiratory support and 85% required vasopressor support. The ICU survival rate was 62%. Survivors experienced lower cumulative FO on the 2 days following CKRT initiation (-4.2% in survivors versus -0.5% in non-survivors, p=0.07). Higher urine output on D1 and D2 after discontinuation of CKRT was associated with successful liberation. Conclusions: In this study of post-HCT children with SOS and MOD who received CKRT, 62% survived until ICU discharge. This survival rate is encouraging as it approximates the survival rates of general pediatric cohorts treated with CKRT. Reducing FO after initiation of CKRT can improve survival in these children.
24 Sep 2024Submitted to Pediatric Blood & Cancer
24 Sep 2024Submission Checks Completed
24 Sep 2024Assigned to Editor
26 Sep 2024Review(s) Completed, Editorial Evaluation Pending
30 Sep 2024Reviewer(s) Assigned
04 Nov 2024Editorial Decision: Revise Minor
12 Nov 20241st Revision Received
12 Nov 2024Submission Checks Completed
12 Nov 2024Assigned to Editor
12 Nov 2024Review(s) Completed, Editorial Evaluation Pending
14 Nov 2024Reviewer(s) Assigned
19 Nov 2024Editorial Decision: Accept